Imatinib
Adjuvant Study 1 (ACOSOG Z9001)
Novartis · Phase 3 · Completed · Enrollment 732
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Imatinib 400 mg for 12 months | resected primary GIST 3 cm or more | 400 mg | ITT | placebo | recurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 monthsrecurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months |